Sunbird Medical Devices: what changed
Sunbird Medical Devices
Largest movements
- Cash -€1,659
down €1,659 (-64.7%), from €2,566 to €907
mainly Investment in fixed assets (net) (-€650) and Trade debts (-€531)
- Financial fixed assets +€650
new in 2025: €650
- Deferred charges and accrued income +€228
new in 2025: €228
- Receivables within one year +€212
up €212 (+19.4%), from €1,090 to €1,302
of which Other amounts receivable: +€623
- Trade debts -€531
down €531 (-59.8%), from €889 to €358
- Profit (loss) carried forward -€57
down €57 (-4.2%), from -€1,362 to -€1,420
- Gross operating margin +€1,703
up €1,703, from -€1,252 to €451
- Financial income -€821
down €821 (-100%), from €821 to €0
- Other operating charges -€472
down €472 (-54.2%), from €871 to €399
- Financial charges +€50
up €50 (+83.9%), from €59 to €109
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €3,656 | €3,087 | -€570 | -15.6% |
| Fixed assets | 21/28 | - | €650 | +€650 | |
| Financial fixed assets | 28 | - | €650 | +€650 | |
| Current assets | 29/58 | €3,656 | €2,437 | -€1,220 | -33.4% |
| Amounts receivable within one year | 40/41 | €1,090 | €1,302 | +€212 | +19.4% |
| Trade receivables | 40 | €627 | €216 | -€411 | -65.6% |
| Other amounts receivable | 41 | €463 | €1,086 | +€623 | +134% |
| Cash at bank and in hand | 54/58 | €2,566 | €907 | -€1,659 | -64.7% |
| Deferred charges and accrued income | 490/1 | - | €228 | +€228 | |
| Total equity and liabilities | 10/49 | €3,656 | €3,087 | -€570 | -15.6% |
| Equity | 10/15 | €1,638 | €1,580 | -€57 | -3.5% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€1,362 | -€1,420 | -€57 | -4.2% |
| Amounts payable | 17/49 | €2,019 | €1,507 | -€512 | -25.4% |
| Amounts payable within one year | 42/48 | €889 | €358 | -€531 | -59.8% |
| Trade debts | 44 | €889 | €358 | -€531 | -59.8% |
| Suppliers | 440/4 | €889 | €358 | -€531 | -59.8% |
| Accrued charges and deferred income | 492/3 | €1,130 | €1,149 | +€19 | +1.7% |
| Other operating charges | 640/8 | €871 | €399 | -€472 | -54.2% |
| Gross operating margin | 9900 | -€1,252 | €451 | +€1,703 | |
| Operating profit (loss) | 9901 | -€2,124 | €52 | +€2,175 | |
| Financial income | 75/76B | €821 | €0 | -€821 | -100% |
| Recurring financial income | 75 | €821 | €0 | -€821 | -100% |
| Financial charges | 65/66B | €59 | €109 | +€50 | +83.9% |
| Recurring financial charges | 65 | €59 | €109 | +€50 | +83.9% |
| Profit (loss) for the period before taxes | 9903 | -€1,362 | -€57 | +€1,305 | +95.8% |
| Profit (loss) for the period | 9904 | -€1,362 | -€57 | +€1,305 | +95.8% |
| Profit (loss) for the period to be appropriated | 9905 | -€1,362 | -€57 | +€1,305 | +95.8% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 7 November 2026 via checked.be.